Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
17.11
-0.53 (-3.00%)
Sep 10, 2026, 11:45 AM HKT
Shanghai Junshi Biosciences Employees
Shanghai Junshi Biosciences had 3,055 employees as of June 30, 2026. The number of employees increased by 152 or 5.24% since the number was reported on December 31, 2025.
Employees
3,055
Change
152
Growth
5.24%
Revenue / Employee
1.14M HKD
Profits / Employee
-166.58K HKD
Market Cap
33.53B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 3,055 | 152 | 5.24% | 3,055 | 0 |
| Dec 31, 2025 | 2,903 | 325 | 12.61% | 2,903 | 0 |
| Dec 31, 2024 | 2,578 | -383 | -12.93% | 2,578 | 0 |
| Dec 31, 2022 | 2,961 | 156 | 5.56% | 2,961 | 0 |
| Dec 31, 2021 | 2,805 | 352 | 14.35% | 2,805 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| Akeso | 4,082 |
| RemeGen | 3,145 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,768 |
| Biocytogen Pharmaceuticals (Beijing) | 1,443 |
Shanghai Junshi Biosciences News
- 14 days ago - Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates - Financial Post
- 7 weeks ago - Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC - GlobeNewsWire
- 3 months ago - Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC - GlobeNewsWire
- 4 months ago - Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026 - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 months ago - Shanghai Junshi announces NMPA acceptance of NDAs for toripalimab injection - TheFly
- 6 months ago - Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications - GlobeNewsWire
- 6 months ago - Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) - PRNewsWire